Investigational Drug Information for Sotrastaurin
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Sotrastaurin?
Sotrastaurin is an investigational drug.
There have been 7 clinical trials for Sotrastaurin.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2010.
The most common disease conditions in clinical trials are Lymphoma, Uveal Neoplasms, and Melanoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Array BioPharma, and Array Biopharma, now a wholly owned subsidiary of Pfizer.
Summary for Sotrastaurin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 425 |
| WIPO Patent Applications | 281 |
| Japanese Patent Applications | 119 |
| Clinical Trial Progress | Phase 2 (2010-04-01) |
| Vendors | 57 |
Recent Clinical Trials for Sotrastaurin
| Title | Sponsor | Phase |
|---|---|---|
| Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation | Novartis | Phase 2 |
| Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation | James Blachly | Phase 2 |
| Trial of AEB071 in Combination With BYL719 in Patients With Melanoma | Richard D. Carvajal | Phase 1 |
Clinical Trial Summary for Sotrastaurin
Top disease conditions for Sotrastaurin
Top clinical trial sponsors for Sotrastaurin
US Patents for Sotrastaurin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
